Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31333261 | 0.96 | HRH3 (0.51) | HRH3NR1H2GPR119SMN1; SMN2USP30 | |
| SCHEMBL29508938 | 0.89 | NR1H2 (0.53) | NR1H2GPR119SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL660403 | 0.89 | NR1H2 (0.53) | NR1H2GPR119SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL25366909 | 0.88 | NR1H2 (0.46) | HRH3NR1H2GPR119SMN1; SMN2USP30 | |
| SCHEMBL23783164 | 0.88 | GPR119 (0.58) | NR1H2GPR119SMN1; SMN2 | |
| SCHEMBL31334152 | 0.88 | HRH3 (0.48) | HRH3NR1H2GPR119SMN1; SMN2USP30 | |
| SCHEMBL25194818 | 0.86 | KDM4E (0.46) | HRH3NR1H2GPR119ALDH1A1TP53 | |
| SCHEMBL31334469 | 0.86 | USP30 (0.42) | HRH3NR1H2GPR119SMN1; SMN2USP30 | |
| SCHEMBL31334894 | 0.86 | USP30 (0.42) | HRH3NR1H2GPR119SMN1; SMN2USP30 | |
| SCHEMBL31334472 | 0.86 | GPR119 (0.57) | NR1H2GPR119SMN1; SMN2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4562007-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240051946-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-02-15 | — | — | US | disclosed |
| WO-2024026083-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026083-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| CN-116745280-A | Bifunctional compounds for degrading EGFR and related methods of use | 百济神州有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116490184-A | Compounds for inhibiting EGFR mutant cancers and pharmaceutical uses thereof | J2H生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022068849-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEIGENE, LTD. (KY) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | EGFR, KRAS, ERBB2 | HRH3 4404/4885NR1H2 2680/4885GPR119 2981/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | HRH3 3471/4885NR1H2 3784/4885GPR119 4240/4885 |
| US-20240051946-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | HRH3 3114/4885NR1H2 3816/4885GPR119 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.